"White House Targets Big Pharma: First 10 Drugs for Medicare Price Negotiations Revealed"
The Biden administration has revealed the first 10 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, marking a significant step towards making costly medications more affordable for older Americans. These drugs, which include Eliquis, Jardiance, Xarelto, Januvia, and Enbrel, among others, accounted for $50.5 billion, or about 20%, of total Part D prescription drug costs from June 2022 to May 2023. The negotiations are expected to save Medicare an estimated $98.5 billion over a decade, but the pharmaceutical industry has filed lawsuits to challenge the process, arguing that it violates their constitutional rights.
- Biden administration unveils first 10 drugs subject to Medicare price negotiations CNBC
- Eliquis and Jardiance Among First Drugs Picked for Medicare Price Negotiations The New York Times
- These are the first 10 drugs subject to Medicare price negotiations CNN
- White House inflicts Big Pharma ills Reuters
- Biden administration unveils 10 drugs subject to Medicare price negotiations The Washington Post
Reading Insights
0
9
6 min
vs 7 min read
93%
1,350 → 98 words
Want the full story? Read the original article
Read on CNBC